Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial

[1]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[2]  T. Delozier,et al.  Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen , 2005, Breast Cancer Research and Treatment.

[3]  M. Zelen.  Theory and Practice of Clinical Trials , 2003 .

[4]  M. Stockler,et al.  Chemotherapy for metastatic breast cancer--when is enough enough? , 1997, European journal of cancer.

[5]  T. Powles,et al.  A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. , 1997, European journal of cancer.

[6]  S. Seeber,et al.  Epirubicin and ifosfamide in metastatic breast cancer. , 1996, Seminars in Oncology.

[7]  U. Veronesi,et al.  Oxford textbook of oncology , 1996 .

[8]  S. Lundgren,et al.  Weekly doxorubicin with or without high-dose medroxyprogesterone acetate in hormone-resistant advanced breast cancer. A randomised study. The Norwegian Breast Cancer Group. , 1994, European journal of cancer.

[9]  H. Mouridsen,et al.  Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. , 1993, European journal of cancer.

[10]  F. Cavalli,et al.  Feasibility of quality of life assessment in a randomized phase III trial of small cell lung cancer--a lesson from the real world--the Swiss Group for Clinical Cancer Research SAKK. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  C. Spurr,et al.  Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. , 1991, The New England journal of medicine.

[12]  J. Carmichael,et al.  Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer , 1990, The Lancet.

[13]  M. Tattersall,et al.  Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. , 1987, The New England journal of medicine.

[14]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[15]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[16]  D. Morton,et al.  Treatment of metastatic disease. , 1979, Advances in surgery.

[17]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.

[18]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.

[19]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[20]  S. George,et al.  Planning the size and duration of a clinical trial studying the time to some critical event. , 1974, Journal of chronic diseases.

[21]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[22]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .